Cidara Therapeutics, Inc. CDTX 深 滬
已收盤 01-07 16:00:00 美东时间
221.38
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 總市值 69.74亿
- 52周最高 221.42
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 總股本 3150.43万
- 歷史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.00
- 每 手 1
- 風險率 68.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多默沙东完成收购产生大额费用 上调2026年业绩指引推进收购计划
经济观察网 默沙东近期披露收购进展及最新业绩指引，已完成对Cidara Therapeutics收购，同时上调2026年营收及每股收益预期。 业务进展情况 近期...
05-06 01:06
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
05-01 01:10
Merck Q1 earnings beat lifts shares; 2026 guidance narrowed
Merck (MRK) was up around 5% premarket on Thursday after it beat top- and bottom-line estimates for Q1 and issued a narrowed outlook for 2026. The Rahway, New Jersey–based company adjusted its guidanc...
04-30 18:59
Merck & Co Inc Stock (MRK) Moved Up by 3.18% on Apr 8: Facts Behind the Movement
• Enlicitide Phase 3 results show significant LDL reduction and safety. • Keytruda approved in EU for platinum-resistant ovarian cancer. • Merck acquired Terns Pharmaceuticals to strengthen pipeline.
04-08 18:15
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms Adds details and background in paragraphs 6-7 Feb 23 (Reuters) - Merck MRK.N said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Ke
02-23 19:34
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results Co expects 2026 sales of $65.5 bln-$67 bln vs analysts' estimate $67.6 bln Reports Q4 sales of $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds analyst comments in paragraphs 5 and 10
02-03 19:40
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds shares in paragraph 3 By Michael Erman Feb 3 (Reut
02-03 19:40
